TNF Pharmaceuticals (TNFA) Stock Analysis

What TNF Pharmaceuticals does

TNF Pharmaceuticals, Inc. is a clinical-stage pharmaceutical firm dedicated to developing advanced therapeutic platforms that tackle the root causes of diseases, rather than just managing symptoms. Its flagship drug platform, MYMD-1, is a small molecule currently undergoing clinical trials. This platform functions by modulating the immune system to regulate TNF-alpha—a key driver of chronic inflammation—and other pro-inflammatory cytokines. MYMD-1 is being developed with the potential to slow aging, extend life, and treat various autoimmune conditions. The company also boasts Supera-CBD, its second innovative platform. Supera-CBD is a novel synthetic derivative of cannabidiol (CBD), designed to enhance and cater to the expanding CBD market, which includes both FDA-approved medications and other unregulated CBD products. Its intended uses span chronic pain relief, addiction treatment, and epilepsy. Founded in 2014, the company was initially known as MyMD Pharmaceuticals, Inc. before rebranding to TNF Pharmaceuticals, Inc. in July 2024. It operates from its headquarters in Baltimore, Maryland.

Key metrics

ETFs linked to TNFA

Broad-market and Healthcare sector ETFs an investor holding TNF Pharmaceuticals is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how TNFA fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for TNF Pharmaceuticals?

TNF Pharmaceuticals trades under the ticker TNFA on NASDAQ.

Which exchange is TNFA listed on?

TNFA is listed on NASDAQ.

What sector does TNF Pharmaceuticals operate in?

TNF Pharmaceuticals is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze TNFA in a portfolio?

PortView shows TNFA's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.